JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Tanaka, K. A. Articles by Levy, J. H. Search for Related Content PubMed PubMed Citation Articles by Tanaka, K. A. Articles by Levy, J. H.

---

CARDIOVASCULAR ANESTHESIOLOGY

Thrombin Generation Assay and Viscoelastic Coagulation Monitors Demonstrate Differences in the Mode of Thrombin Inhibition Between Unfractionated Heparin and Bivalirudin

From the Department of Anesthesiology, Emory University School of Medicine, Atlanta, Georgia.

Address correspondence and reprint requests to Kenichi A. Tanaka, MD, MSc, Emory University Hospital, 1364 Clifton Road, NE, Atlanta, GA. Address e-mail to kenichi.tanaka{at}emoryhealthcare.org.

Abstract

BACKGROUND: Coagulation tests, such as activated partial thromboplastin time and activated clotting time, are used to monitor the effects of unfractionated heparin and the direct thrombin inhibitor, bivalirudin. These tests reflect only the initial phase of blood clotting, when <5% of thrombin has been formed. In this study, we sought to determine if similar increases in activated partial thromboplastin time or activated clotting time due to heparin or bivalirudin would reflect the same degree of inhibition of thrombin formation.

METHODS: Thrombin formation was evaluated in platelet-poor plasma activated in the presence of heparin (0–5 U/mL) or bivalirudin (0–30 µg/mL) using a thrombin generation assay (Thrombinoscope^TM). Prothrombin activation was measured by prothrombin fragment 1.2 (F1.2) formation. Thrombus formation was further evaluated in kaolin-activated whole blood samples containing heparin (1.5 or 2.5 U/mL) or bivalirudin (12.5 or 25 µg/mL) using Sonoclot^TM and thromboelastography.

RESULTS: Based on the Thrombinoscope results, increasing concentrations of bivalirudin and heparin progressively delayed the onset of thrombin formation, but only heparin dose-dependently decreased the amount of thrombin generated. Heparin and bivalirudin delayed the onset of F1.2 formation, but there was no difference in peak F1.2 levels between bivalirudin and non-anticoagulated samples (206 ± 28.2 vs 182 ± 23.9 nmol/L, P = 0.09). In heparinized samples, F1.2 levels were significantly lower (75.7 ± 29.8 nmol/L, P < 0.05) than controls. Heparin and bivalirudin prolonged the onset of clotting on viscoelastic monitors, but only heparin decreased the rate of thrombus formation.

CONCLUSION: Thrombus formation kinetics differs between heparin and bivalirudin despite similar prolongation of clotting test values.

This article has been cited by other articles:

				D. Dirkmann, A. A. Hanke, K. Gorlinger, and J. Peters Hypothermia and Acidosis Synergistically Impair Coagulation in Human Whole Blood Anesth. Analg., June 1, 2008; 106(6): 1627 - 1632. [Abstract] [Full Text] [PDF]

				M. T. Ganter and C. K. Hofer Coagulation Monitoring: Current Techniques and Clinical Use of Viscoelastic Point-of-Care Coagulation Devices Anesth. Analg., May 1, 2008; 106(5): 1366 - 1375. [Abstract] [Full Text] [PDF]

Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999